Urinary incontinence in women: a review

ES Lukacz, Y Santiago-Lastra, ME Albo, L Brubaker - Jama, 2017 - jamanetwork.com
Importance Urinary incontinence, the involuntary loss of urine, is a common health condition
that may decrease quality of life. Ten to twenty percent of women and up to 77% of women …

Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women

SL Wallace, LD Miller, K Mishra - Current Opinion in Obstetrics …, 2019 - journals.lww.com
Pelvic floor physical therapy in the treatment of pelvic flo... : Current Opinion in Obstetrics and
Gynecology Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women …

Incontinence after prostate treatment: AUA/SUFU guideline

JS Sandhu, B Breyer, C Comiter, JA Eastham… - The Journal of …, 2019 - auajournals.org
Purpose: Urinary incontinence after prostate treatment (IPT) is one of the few urologic
diseases that is iatrogenic, and, therefore, predictable and perhaps preventable. Evaluation …

[HTML][HTML] Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and …

C Kelleher, Z Hakimi, R Zur, E Siddiqui, K Maman… - European urology, 2018 - Elsevier
Background Mirabegron is an established treatment alternative to antimuscarinic therapy for
patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase …

International Continence Society best practice statement for use of sacral neuromodulation

HB Goldman, JC Lloyd, KL Noblett… - Neurourology and …, 2018 - Wiley Online Library
Aims Sacral neuromodulation (SNM) is an accepted therapy for a variety of conditions.
However, despite over 20 years of experience, it remains a specialized procedure with a …

The cognitive effect of anticholinergics for patients with overactive bladder

B Welk, K Richardson, JN Panicker - Nature Reviews Urology, 2021 - nature.com
Overactive bladder (OAB) is often treated with medications that block the cholinergic
receptors in the bladder (known as anticholinergics). The effect of this medication class on …

Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation

S Siegel, K Noblett, J Mangel, J Bennett… - The Journal of …, 2018 - auajournals.org
Purpose: We evaluated the therapeutic success rate, changes in quality of life and safety of
sacral neuromodulation 5 years after InterStim™ implantation. Included in study were …

International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of …

D Staskin, J Frankel, S Varano, D Shortino… - The Journal of …, 2020 - auajournals.org
Purpose: We assessed efficacy, safety and tolerability of vibegron, a novel, potent, highly
selective β3-adrenoceptor agonist, administered 12 weeks at 75 mg once daily to patients …

Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: randomized …

I Ramírez‐García, L Blanco‐Ratto… - Neurourology and …, 2019 - Wiley Online Library
Aim To evaluate the non‐inferiority of the transcutaneous electrical stimulation technique, as
compared with the percutaneous therapy (PTNS), regarding the efficacy in symptoms and …

Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta‐3 agonist: a population‐based …

B Welk, E McArthur - BJU international, 2020 - Wiley Online Library
Objective To determine if there is an increased risk of dementia among patients with
overactive bladder (OAB) starting an anticholinergic medication compared to those starting a …